Skip to main navigation
Logo
Investors

Event Details

Webcast Image Catalyst Biosciences, Inc. at the World Federation of Hemophilia 2018 Congress

May 22, 2018 12:00 PM EDT

Supporting Materials

Phase 1 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant ISU304/CB 2679d: Pharmacokinetics, Activity and Safety 1.1 MB

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts

Investor Relations

  • Overview
  • Press Releases
  • Events and Presentations
    • Scientific Presentations and Publications
  • Financials & Filings
  • Stock Information
  • Corporate Governance
  • Investor FAQ
  • Contact Us

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • About
    • Management Team
    • Board of Directors
    • Strategic Partners
    • Contact Us
  • Pipeline
    • Hemostasis
    • Anti-Complement
  • Science
  • News
  • Investors

    Investor header menu

    • Press Releases
    • Events and Presentations
    • Financials & Filings
    • Stock Information
      • Stock Quote
      • Stock Chart
    • Corporate Governance
      • Leadership Team
      • Board of Directors
      • Committee Composition
    • Investor FAQ
    • Contact Us
  • Careers
  • Home
  • Contact
  • Home
  • Contact
  • About
    • Management Team
    • Board of Directors
    • Strategic Partners
    • Contact Us
  • Pipeline
    • Hemostasis
    • Anti-Complement
  • Science
  • News
  • Investors
    • Press Releases
    • Events and Presentations
    • Financials & Filings
    • Stock Information
      • Stock Quote
      • Stock Chart
    • Corporate Governance
      • Leadership Team
      • Board of Directors
      • Committee Composition
    • Investor FAQ
    • Contact Us
  • Careers
    • Benefits
  • Terms of Use
  • Privacy Policy
  • LinkedIn
© 2021 Catalyst BiosciencesAll rights reservedWebsite Design: Hane Chow, Inc.
  • Terms of Use
  • Privacy Policy
  • LinkedIn
  • Twitter
  • Facebook